Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2-breast cancer.

被引：0
|
作者：
Landsman-Blumberg, Pamela
Namjoshi, Madhav
Thomson, Erin
Johnson, William
机构：
[1] Thomson Reuters, Washington, DC USA
[2] Novartis Oncol, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
593
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Aromatase inhibitor failure: predictors and time to first failure among women with metastatic ER+/HER2-breast cancer in the US
    Thomson, E.
    Namjoshi, M.
    Landsman-Blumberg, P.
    Chu, B. C.
    [J]. CANCER RESEARCH, 2012, 72
  • [2] EVALUATION OF AROMATASE INHIBITOR UTILIZATION AND FAILURE IN POST-MENOPAUSAL WOMEN WITH ADVANCED ER+/HER2-BREAST CANCER
    Landsman-Blumberg, P.
    Namjoshi, M.
    Thomson, E.
    Johnson, W.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A229 - A230
  • [3] Evaluation of Aromatase Inhibitor failure and total healthcare expenditures among post-menopausal women with metastatic ER+/HER2-breast cancer in the US
    Namjoshi, M.
    Landsman-Blumberg, P.
    Thomson, E.
    Chu, B. C.
    [J]. CANCER RESEARCH, 2012, 72
  • [4] TILs in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Viale, G.
    Curigliano, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 3 - 3
  • [5] MODERN CHEMOTHERAPY USE AMONG YOUNG WOMEN WITH EARLYSTAGE ER+/HER2-BREAST CANCER
    Poorvu, Philip
    Gelber, Shari
    Rosenberg, Shoshana
    Ruddy, Kathryn
    Tamimi, Rulla
    Peppercorn, Jeffrey
    Schapira, Lidia
    Borges, Virginia
    Come, Steven
    Collins, Laura
    Warner, Ellen
    Partridge, Ann
    [J]. BREAST, 2018, 41 : S18 - S18
  • [6] Estetrol for treatment of advanced ER+/HER2-breast cancer
    Schmidt, Marcus
    Hoenig, Arnd
    Zimmerman, Yvette
    Verhoeven, Carole
    Almstedt, Katrin
    Battista, Marco
    Lenhard, Hans Georg
    Krijgh, Jan
    Bennink, Herjan Coelingh
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [7] Real-world starting dose and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer.
    Patt, Debra A.
    Liu, Xianchen
    Li, Benjamin
    Mcroy, Lynn
    Layman, Rachel M.
    Brufsky, Adam
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Response of persistent metastatic ER+/Her2-breast cancer treated with fulvestrant plus enzalutamide
    Richer, Jennifer
    Spoelstra, Nicole
    Winchester, Alyse
    Wulfkuhlue, Julia
    Gallagher, Rosa
    Sams, Sharon
    Vidal, Gregory
    Kabos, Peter
    Diamond, Jennifer
    Shagisultanova, Elena
    Afghahi, Anosheh
    Mayordomo, Jose
    McSpadded, Tessa
    Crawford, Gloria
    Borges, Virginia
    Gao, Dexiang
    Petricoin, Emanuel
    Elias, Anthony
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [9] Dysregulated expression of repetitive DNA in ER+/HER2-breast cancer
    Yandim, Cihangir
    Karakulah, Gokhan
    [J]. CANCER GENETICS, 2019, 239 : 36 - 45
  • [10] Tumor infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer
    Criscitiello, C.
    Vingiani, A.
    Maisonneuve, P.
    Viale, G.
    Esposito, A.
    Viale, G.
    Curigliano, G.
    [J]. CANCER RESEARCH, 2019, 79 (04)
12345